Pharmacology of drugs used in premature ejaculation
Abstract
Our understanding of the pharmacology of premature ejaculation is somewhat limited compared to other andrological and urological disorders. It is largely based on clinical observation of data from agents e.g. dapoxetine that although designated as “selective” usually have little actual pharmacological selectivity. The situation is further complicated by the lack of a reasonably predictive animal model. It remains however that 5-HT and oxytocin are involved in the ejaculatory reflex and modulators of these functions could provide a reasonable starting point for de novo drug development. It is unlikely that topically involved agents will evolve much beyond “desensitising agents” or the rationally designed TEMPE.
Read the paper
Related studies
- Improving the translation of search strategies using the Polyglot Search Translator: a randomized controlled trial
- Nutritional, Physical, Cognitive, and Combination Interventions and Frailty Reversal Among Older Adults: A Randomized Controlled Trial
- Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
- A randomized, controlled trial of oral propranolol in infantile hemangioma
- Clinical phenotypes of delirium during critical illness and severity of subsequent long-term cognitive impairment: a prospective cohort study
- Increased physical activity improves sleep and mood outcomes in inactive people with insomnia: a randomized controlled trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.